Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GS 0189

Next Previous
Drug Profile

GS 0189

Alternative Names: FSI-189; FSI89; GS-0189

Latest Information Update: 02 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Forty Seven
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Macrophage stimulants; SIRPA protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Unspecified

Most Recent Events

  • 13 May 2022 Gilead Sciences terminated a phase-I trial due to sponsor's decision to discontinue development of this molecule in Non-Hodgkin's lymphoma ( Monotherapy, Second-line therapy or greater) in USA (IV) (NCT04502706)
  • 13 May 2022 Gilead Sciences terminated a phase-I trial due to sponsor's decision to discontinue development of this molecule in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT04502706)
  • 28 Apr 2022 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top